GB2597323A — Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
Assigned to GW Research Ltd · Expires 2022-01-26 · 4y expired
What this patent protects
The use of cannabidiol (CBD) for the treatment of epileptic seizures associated with rare epilepsy syndromes, the seizures treated are in patients diagnosed with a Gephyrin (GPHN) mutation. In a further embodiment the types of seizures include tonic, and tonic-clonic seizures. Pr…
USPTO Abstract
The use of cannabidiol (CBD) for the treatment of epileptic seizures associated with rare epilepsy syndromes, the seizures treated are in patients diagnosed with a Gephyrin (GPHN) mutation. In a further embodiment the types of seizures include tonic, and tonic-clonic seizures. Preferably the CBD comprises greater than 98% (w/w) CBD and less than or equal to 2% (w/w) of other cannabinoids. Where the CBD is given concomitantly with one or more other anti-epileptic drugs (AED) including clobazam, lamotrigine and zonisamide. Preferably the dose of CBD is between 5 mg/kg/day to 50 mg/kg/day. Preferably the CBD used is in the form of a botanically derived purified CBD, but a synthetically produced CBD can alternatively be used.
Drugs covered by this patent
- Epidiolex (CANNABIDIOL) · Jazz Pharms Res
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.